Dr T has confirmed somewhere else that new safety trials are not required and it can use the old data under the 505(b)(2) pathway.
Ann: Race Develops Improved IV Formulation of Zantrene, page-19
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.72 |
Change
0.020(1.18%) |
Mkt cap ! $296.3M | |||
| Open | High | Low | Value | Volume |
| $1.74 | $1.75 | $1.70 | $138.4K | 80.22K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1200 | $1.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.73 | 160 | 1 |
View Market Depth
| Last trade - 13.18pm 25/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |